Unlock this StockReport nowClick to Unlock

Mabion SA Share Price

MAB PLN77.6 0.4  0.5%
22/03/19
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 TTM 2018E 2019E CAGR / Avg
Revenue PLNm
Operating Profit PLNm
Net Profit PLNm
EPS Reported PLN
EPS Normalised PLN
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps PLN
Capex ps PLN
Free Cashflow ps PLN
Dividends
Dividend ps PLN
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc PLNm
Working Capital PLNm
Net Fixed Assets PLNm
Net Debt PLNm
Book Value PLNm
Average Shares m
Book Value ps PLN

FINANCIAL BRIEF: For the nine months ended 30 September 2018, Mabion SA revenues was not reported. Net loss increased 35% to PLN52.3M. Higher net loss reflects Foreign Exchange Gain decrease of 70% to PLN1.4M (income), Foreign Exchange Loss increase from PLN0K to PLN3.2M (expense), General/Admin. Expense - Other increase of 36% to PLN6.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -PLN3.27 to -PLN4.10. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
E-
E-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2018
31st Dec 2019

Price Target: PLN171.2
(+120.61% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (PLN) (PLN) (PLN) (PLN) (PLN) (PLN)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Mabion SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Santander Brokerage Poland Lukasz Kosiarski , Ipopema Securities Michal Bugajski ,

Profile Summary

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Directors: Artur Chabowski (CMG) , Maciej Wieczorek (VSU) , Slawomir Jaros (MGB) , Jaroslaw Walczak (MGB) , David James (IND) , Robert Konski (IND) 52, Tadeusz Pietrucha (IND) , Jozef Banach (SUB) , Krzysztof Kaczmarczyk (SUB) 42,

No. of Employees: 160 No. of Shareholders: n/a


Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated October 29, 2009
Public Since August 10, 2010
Shares in Issue 13,720,772
Free Float 8.28m (60.3%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Warsaw Stock Exchange
Eligible for an ISA? a SIPP?

MAB Share Price Performance MAB Share Price Quote
PLN77.6
0.4  0.5%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest MAB News Announcements (delayed)

Upcoming MAB Events
Friday 28th June, 2019 (estimate)
Mabion SA Annual Shareholders Meeting

Recent ↓
Thursday 28th June, 2018
Mabion SA Annual Shareholders Meeting
Wednesday 18th April, 2018
Mabion SA Extraordinary Shareholders Meeting
Thursday 16th February, 2017
Mabion SA Extraordinary Shareholders Meeting


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy MAB

Access MAB Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis